Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here


Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

 
Bookmark and Share
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
Diabetes News
Clinical trials testing therapies for diabetes

Latest Top (15) News


Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs
Conditions:   PreDiabetes;   Obesity
Interventions:   Other: EHR gaps;   Other: Bulk outreach;   Other: Dietician call
Sponsor:   Kaiser Permanente
Not yet recruiting - verified June 2017

Fri, 23 Jun 2017 12:00:00 EDT


Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Conditions:   Heart Failure Acute;   Heart Failure,Congestive;   Heart Failure; With Decompensation
Interventions:   Drug: Empagliflozin 10 MG;   Drug: Placebo Oral Tablet
Sponsor:   University Medical Center Groningen
Not yet recruiting - verified June 2017

Fri, 23 Jun 2017 12:00:00 EDT


Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
Sponsor:   AstraZeneca
Not yet recruiting - verified June 2017

Thu, 22 Jun 2017 12:00:00 EDT


The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Condition:   Nonproliferative Diabetic Retinopathy
Interventions:   Drug: AKB-9778;   Drug: Placebo
Sponsor:   Aerpio Therapeutics
Recruiting - verified June 2017

Thu, 22 Jun 2017 12:00:00 EDT


Bexagliflozin Drug/Drug Interaction Study With Digoxin
Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Digoxin
Sponsor:   Theracos
Not yet recruiting - verified June 2017

Wed, 21 Jun 2017 12:00:00 EDT


Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
Condition:   Hypogonadism, Male
Interventions:   Drug: SOV2012-F1;   Drug: AndroGel
Sponsors:   Marius Pharmaceuticals;   INC Research
Not yet recruiting - verified June 2017

Wed, 21 Jun 2017 12:00:00 EDT


Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
Conditions:   Heart Failure With Normal Ejection Fraction;   Sleep Apnea
Intervention:   Device: ASV Therapy
Sponsor:   ResMed
Not yet recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Białystok PLUS - Polish Longitudinal University Study
Conditions:   Cardiovascular Diseases;   Diabetes;   Neuro-Degenerative Disease;   Obesity;   Pulmonary Disease;   Neoplastic Disease
Intervention:   Other: Discover of novel risk factors.
Sponsors:   Medical University of Bialystok;   University Medicine Greifswald;   City of Białystok;   Marshall’s Office of Podlaskie Voivodship
Enrolling by invitation - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Characterization of Heart Failure With Preserved Ejection Fraction
Condition:   Fibrosis Estimated by cMR Ant Biomarkers
Interventions:   Diagnostic Test: cMR;   Biological: biomarker
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Corazon de la Familia (Heart of the Family)
Conditions:   Risk Reduction Behavior;   Diabetes Mellitus, Type 2;   Cardiovascular Diseases
Interventions:   Behavioral: Family-focused intervention arm;   Behavioral: Individual-focused intervention arm
Sponsors:   University of Kentucky;   National Institute of Nursing Research (NINR);   National Institutes of Health (NIH)
Not yet recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Creating Healthy Environments for Chicago Kids
Condition:   Childhood Obesity
Intervention:   Behavioral: Family-based pediatric obesity treatment
Sponsors:   Rush University Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Effect of Different Exercises on Musculoskeletal Pain,Glucose Level and Quality of Life Among Patients With Diabetes
Condition:   Diabetes
Interventions:   Other: Rebound exercise;   Other: Circuit training exercise
Sponsor:   University of KwaZulu
Not yet recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes
Conditions:   Diabetes Mellitus, Type 1;   Autoimmune Diseases;   Diabetes Mellitus;   Endocrine System Diseases;   Glucose Metabolism Disorders;   Immune System Diseases;   Metabolic Diseases
Interventions:   Drug: Glutamine vs. Placebo;   Other: Exercise
Sponsor:   Nemours Children's Clinic
Recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Impact of Perioperative Shedding of the Endothelial Glycocalyx on the Incidence of Postoperative Acute Kidney Injury in Patients Undergoing Valvular Heart Surgery.
Condition:   Valvular Heart Disease
Intervention:  
Sponsor:   Yonsei University
Not yet recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT


Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Pioglitazone + Metformin;   Drug: Placebo Oral Tablet
Sponsor:   Sun Yat-sen University
Recruiting - verified June 2017

Tue, 20 Jun 2017 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News


FDA Tackles Drug Competition to Improve Patient Access
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of generic drug applications where competition is limited.

Tue, 27 Jun 2017 09:57:00 -0400


Statement from FDA Commissioner Scott Gottlieb, M.D., on the importance of the Drug Quality and Security Act and overseeing the safety of compounded drugs
In late 2012, the United States faced the most serious outbreak associated with contaminated compounded drugs in recent history, involving hundreds of people, in many states, who developed fungal infections related to a compounded product. It was an incident that resulted in dozens of deaths.

Mon, 26 Jun 2017 20:06:00 -0400


FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease
The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. The subcutaneous route of administration allows for easier at-home self-injection by the patient or caregiver, once proper training is received.

Thu, 22 Jun 2017 17:15:00 -0400


U.S. Marshals seize adulterated food from a Minnesota warehouse
The U.S. Food and Drug Administration announced that on June 15, the U.S. Marshals Service seized food products held at Professional Warehouse and Distribution, Inc., in St. Paul, Minnesota. The food products seized are worth approximately $73,000 and include, among other things, barley flour, spices, pasta, dried beans, tea and cookies.

Tue, 20 Jun 2017 13:24:00 -0400


Statement from FDA Commissioner Scott Gottlieb, M.D., on the 2016 National Youth Tobacco Survey results
While the latest numbers from the 2016 National Youth Tobacco Survey are encouraging, it is critical that we work to ensure this downward trend continues over the long term across all tobacco products. Every day in the U.S., more than 2,500 youth under the age of 18 smoke their first cigarette and more than 400 youth become daily cigarette smokers. It is also clear from these most recent numbers that youth are continuing to experiment with, or becoming regular users of, a wide range of other tobacco products.

Thu, 15 Jun 2017 13:49:00 -0400


Sonar Products ordered to cease operations, Stratus Pharmaceuticals ordered to cease distributing unapproved drugs
Today, U.S. District Judge Kathleen M. Williams for the Southern District of Florida entered a consent decree of permanent injunction between the United States and Stratus Pharmaceuticals Inc. of Miami, Florida, Sonar Products Inc. of Carlstadt, New Jersey and two of the companies’ officers, Alberto Hoyo and Juan Carlos Billoch.

Thu, 15 Jun 2017 12:33:00 -0400


Statement from FDA Commissioner Scott Gottlieb, M.D. – FDA is taking new steps to help assess opioid drugs with abuse-deterrent properties
Last month, I asked my colleagues at the FDA to identify what additional and more forceful steps the FDA can take, on top of the vigorous work the agency is already doing, to address the crisis of opioid addiction. Everyone at the FDA is committed to focusing on all aspects of the epidemic. The new policy steps that we announced included the formation of a steering committee to examine additional regulatory and policy actions that we can take to combat this crisis. This steering committee will place particular emphasis on evaluating efforts we can take to reduce the number of new cases of addiction.

Tue, 13 Jun 2017 09:03:00 -0400


FDA requests removal of Opana ER for risks related to abuse
Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.

Thu, 08 Jun 2017 16:15:00 -0400


FDA expands use of Sapien 3 artificial heart valve for high-risk patients
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.

Mon, 05 Jun 2017 15:44:00 -0400


FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Tue, 30 May 2017 16:49:00 -0400
Diabetes news from the American Diabetes Association

Latest Top (5) News